Cramer: Neutral on MannKind's (MNKD) Afrezza

NEW YORK (TheStreet) -- TheStreet's Jim Cramer says MannKind  (MNKD) is difficult to gauge because many people felt its inhaled insulin drug Afrezza would fail. As a result, 28% of the float was short and any positive news would send the stock upward.

Cramer says some believe the stock will go down again almost immediately. On the other hand, those who believe in the drug say this is the beginning of a major move for the stock because Mannkind has already spent so much money trying to get Afrezza developed. 

Cramer remains "completely neutral" on this because "sometimes it's just better to admit that you don't know where something's going."

Must Read: Mannkind Afrezza FDA Panel Epilogue Plus a Mea Culpa

Must Watch: Jim Cramer is Neutral on Mannkind's Afrezza Inhaled Insulin

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

MNKD Chart

MNKD data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

More from Markets

P&G, GE and IBM Need to Innovate; Has Starbucks' Stock Grown Ice Cold?--ICYMI

P&G, GE and IBM Need to Innovate; Has Starbucks' Stock Grown Ice Cold?--ICYMI

Is Best Buy Sleeping With the Enemy With Amazon Partnership?

Is Best Buy Sleeping With the Enemy With Amazon Partnership?

Sprint, T-Mobile Might Have to Do More Than Make Promises to Get Deal Approved

Sprint, T-Mobile Might Have to Do More Than Make Promises to Get Deal Approved

Video: The S&P 500 Is Failing to Make New Highs

Video: The S&P 500 Is Failing to Make New Highs

Dow, S&P 500 and Nasdaq Finish Lower as Apple, P&G Slump

Dow, S&P 500 and Nasdaq Finish Lower as Apple, P&G Slump